Dr. Lindeman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
75 Francis Street Amory 3
Brigham And Womens Hospital Department Of Pathology
Boston, MA 02115Phone+1 617-732-6790
Education & Training
- University of California San Francisco School of MedicineResidency, 1994 - 1999
- University of Rochester School of Medicine and DentistryClass of 1994
Certifications & Licensure
- CA State Medical License 1996 - Present
- NY State Medical License 2022 - 2026
- MA State Medical License 2000 - 2023
- American Board of Pathology Anatomic Pathology & Clinical Pathology
- American Board of Pathology Molecular Genetic Pathology
Publications & Presentations
PubMed
- 1169 citationsStandards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Patholo...Marilyn M. Li, Michael B. Datto, Eric J. Duncavage, Shashikant Kulkarni, Neal I. Lindeman
The Journal of Molecular Diagnostics. 2017-01-01 - 980 citationsMolecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, Int...Neal I. Lindeman, Philip T. Cagle, Mary Beth Beasley, Dhananjay Chitale, Sanja Dacic
Journal of Thoracic Oncology. 2013-07-01 - 11 citationsPhase I Trial of a Tablet Formulation of Pilaralisib, a Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid TumorsGerald M. Edelman, Jordi Rodon, Joanne Lager, Christelle Castell, Jason Jiang
The Oncologist. 2018-04-01
Press Mentions
- Upcoming Lung Cancer Molecular Testing Guidelines Address 7 QuestionsAugust 28th, 2024
- Specialists Launch Revised Lung Most Cancers Testing PointersAugust 23rd, 2024
- International Lung Cancer Experts Seek Public Comments on Updated Molecular Testing Guideline to Improve Patient Selection and Targeted TherapiesAugust 22nd, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: